Results 231 to 240 of about 26,004 (264)

Real-world predictive models for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer. [PDF]

Contemp Oncol (Pozn)
Adamczuk-Nurzyńska A, Nurzyński P, Brzozowska M, Jewczak M, Śliwczyński A.   +4 more
europepmc   +1 more source

Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible? [PDF]

World J Gastroenterol
Chen JQ, Lan X.
europepmc   +1 more source

Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial. [PDF]

Breast Cancer Res
Liu M, Zou, Zhang N, Zhou W, Pan X, Deng Y, Yue Y, Wu J, Liang X, Chen M, Zeng X.   +10 more
europepmc   +1 more source

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis. [PDF]

ESMO Open
Trovato G, Rossini D, Guidolin A, Su YY, Shan YS, Chiang NJ, Chou WC, Bai LY, Bagalà C, Bensi M, Niger M, Marchesi S, Garattini SK, Michelotti A, Pretta A, Scartozzi M, Vivaldi C, Bartalini L, Procaccio L, Bergamo F, Antonuzzo L, Chen LT, Salvatore L, Tortora G.   +23 more
europepmc   +1 more source

A phase II clinical trial on the efficacy and safety of carboplatin plus nab-paclitaxel in chemotherapy-naive advanced or recurrent thymic epithelial tumors: protocol of Nab-TET. [PDF]

J Thorac Dis
Hayashi F, Matsuo M, Takemoto S, Ogata R, Umeyama Y, Nakatomi K, Ikeda T, Sugasaki N, Doi S, Kitazaki T, Akagi K, Tomono H, Honda N, Dotsu Y, Taniguchi H, Gyotoku H, Fukuda M, Soda H, Mukae H.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nab-Paclitaxel related cystoid macular edema.

La Clinica terapeutica, 2022
Nab-paclitaxel is a chemotherapeutic drug used to treat various solid malignant tumors. It was conceived with a solvent free formulation to overcome toxicity events and hypersensitivity reactions associated with paclitaxel. However, it still carries ocular adverse effects.
Di Pippo, M, Di Staso, F, De Ponte, C, Fragiotta, S, Abdolrahimzadeh, S   +4 more
openaire   +2 more sources

Le nab-paclitaxel

Bulletin du Cancer, 2015
Resume Le paclitaxel est classiquement utilise dans un vaste eventail d’indications en oncologie. Le nab-paclitaxel est synthetise par un processus d’homogeneisation a haute pression du paclitaxel en presence d’albumine humaine et il a ete initialement developpe pour diminuer la toxicite generalement associee au cremophor du paclitaxel soluble et ...
Daniel Lopez-Trabada Ataz, Sarah Dumont, Thierry André   +2 more
openaire   +1 more source

Nab-paclitaxel: A flattering facelift

Critical Reviews in Oncology/Hematology, 2014
The application of nanotechnology in oncology has increased the efficacy and efficiency of some cytotoxic agents. The paradigm in this field is nab-paclitaxel, a soluble form of paclitaxel that is linked to albumin nanoparticles. The development of nanotechnology as a delivery system for paclitaxel has provided better pharmacokinetic and ...
A, Viúdez, N, Ramírez, I, Hernández-García, F L, Carvalho, R, Vera, M, Hidalgo   +5 more
openaire   +2 more sources

Cystoid macular edema induced by nab-paclitaxel

Breast Cancer, 2012
Cystoid macular edema (CME) is a rare complication of taxane-based chemotherapy. We encountered a patient who developed CME during treatment with nab-paclitaxel for metastatic breast cancer. Early detection of this disease enables continuation of appropriate treatment without reducing the quality of life for patients with end-stage disease.
Yuko, Tanaka, Hiroko, Bando, Hisato, Hara, Yasuaki, Ito, Yoshifumi, Okamoto   +4 more
openaire   +2 more sources

Nab-paclitaxel in patients with metastatic melanoma

Expert Review of Anticancer Therapy, 2015
Cutaneous melanoma is one of the most aggressive and resistant malignancies in humans. Until recently, progress in the treatment of metastatic melanoma remained dormant for nearly two decades. However, recent advances in immune and targeted therapeutic approaches have led to dramatic and paradigm-shifting advances in the management of metastatic ...
Roberto A, Leon-Ferre, Svetomir N, Markovic   +1 more
openaire   +2 more sources